Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)
This protocol is designed to gather a small amount of blood for extraction of DNA for the study of the genetic basis of diabetes. The study population will include individuals with known diabetes, and controls without diabetes. Investigators aim to understand the genetics of diabetes, and will use the cells and serum from this blood to perform genotyping and gene expression studies of individuals with diabetes and relevant controls.
Type 2 Diabetes Mellitus
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)|
Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained. The goal is to find single nucleotide polymorphims (SNP), small changes in single genes that affect disease risk, to see if they correlate with diabetes. Serum will be stored for future studies, for a period of 6 years, to look at levels of proteins. Subjects who consent to participate in this study will have their serum stored for up to 6 years, inorder to be used for future studies on genomics.
|Study Start Date:||June 2009|
|Estimated Study Completion Date:||June 2014|
Individuals with diabetes that fit eligibility criteria.
Individuals without history of diabetes.
This protocol is designed to collect a small amount of blood for extraction of DNA (genetic material) for the study of the genetic basis of diabetes. The study population will include individuals with known diabetes and controls without diabetes. Additionally, this protocol will recruit individuals from the following locations: the Qatar Diabetes Association, the governmental ministries of Qatar, and subjects who have participated in Dr. Bener's HMC protocol #231 entitled "A preliminary study of genetic pre-disposition to diabetic mellitus in the state of Qatar." Individuals with diabetes may also be recruited from the Hamad Hospital outpatient adult diabetes clinics (there are eight diabetes clinics each week) and/or from the population of subjects who previously participated in Dr. Mushlin's IRB approved protocol #0608008703 entitled "Comparing the Clinical Management and Genetic Markers of Diabetes in Qatar to International Standards" at Hamad Medical Corporation or IRB approved protocol #0602008388 entitled "The Impact of Cardiac and Genetic Risk Factors on Acute Myocardial Infarction and Cerebrovascular Stroke in Qatar: A Case-Control Study". In this protocol, researchers will survey medical records of patients with diabetes, in order to study the clinical characteristics of these individuals, and the researchers will collect blood to evaluate the genetic characteristics of individuals with diabetes. The researchers will also collect blood samples of individuals without diabetes to serve as control.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01172743
|Contact: Charleen Hollmann, PhD, RNemail@example.com|
|Contact: Denesy Mancenido, BAfirstname.lastname@example.org|
|Hamad Medical Corporation||Recruiting|
|Contact: Alya A Al-Shakaki +974-492-8445 email@example.com|
|Principal Investigator: Mahmoud Zirie, MD|
|Principal Investigator:||Ronald G Crystal, MD||Weill Cornell Medical College, NY and Qatar|